title: Investigation of the blood-brain barrier for IgG in inflammatory syndromes of the central nervous system.
abstract: To investigate whether an intravenously administered compound of the IgG class is able to penetrate the CSF barrier despite its high molecular weight, 12 hepatitis B surface antibody (anti-HBs)-negative patients received 20 ml each of a beta-propiolactone-treated IgG compound with a high anti-HBs titer (1:115,000) as a marker. 8 had an inflammatory CSF syndrome. In cases of inflammatory CSF syndromes, significantly more marked IgG crossed the blood-brain barrier, this could be of considerable clinical importance.
mesh_terms: D000328:Adult; D001692:Biological Transport; D001812:Blood-Brain Barrier; D002493:Central Nervous System Diseases / Q000134:cerebrospinal fluid*; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007074:Immunoglobulin G / Q000134:cerebrospinal fluid / Q000378:metabolism*; D007136:Immunoglobulins / Q000008:administration & dosage; D007249:Inflammation / Q000134:cerebrospinal fluid*; D007275:Injections, Intravenous
chemical_list: D007074:Immunoglobulin G; D007136:Immunoglobulins